Physician profile
Michael P Link
NPI 1982742862
$37,233.47
in general payments reported to CMS, 2019-2025
8 companies · $13K in 2025
The $13K reported for 2025 was more than what 88% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,648 · 2020: $5,763 · 2021: $9,635 · 2022: $3,973 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Travel and Lodging: $1,278 · Food and Beverage: $87.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,850.00 |
| Travel and Lodging | $1,277.96 |
| Food and Beverage | $87.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11,463.79 | 2020-2025 | |
| Incyte Corporation | $7,382.50 | 2019-2022 | |
| Janssen Research & Development, LLC | $6,501.77 | 2025 | Darzalex |
| Blueprint Medicines Corporation | $4,500.00 | 2021 | |
| Eli Lilly and Company | $3,770.75 | 2019 | |
| Beigene USA, INC. | $3,500.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $114.66 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.